SC
WHWK

Stempoint Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Stempoint Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68M Buy
1,021,037
+81,668
+9% +$340K 0.81% 39
2026
Q1 		$3.24M Sell
939,369
-519,438
-36% -$1.63M 0.62% 45
2025
Q4 		$3.53M Buy
1,458,807
+1,034,725
+244% +$2.37M 0.61% 47
2025
Q3 		$806K Buy
+424,082
New +$780K 0.16% 68

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's WHWK Position: Q2 2026 in Review

Stempoint Capital increased its Whitehawk Therapeutics (WHWK) stake by 8.7% in Q2 2026, buying an estimated $340K and bringing the position to 1,021,037 shares worth $4.68M. The position accounts for 0.81% of the portfolio, ranked #39.

Stempoint Capital first reported a position in WHWK in Q3 2025 and has held it in 4 quarters since. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Stempoint Capital held 1,021,037 shares of Whitehawk Therapeutics worth $4.68M as of Q2 2026.
  • Stempoint Capital bought 81,668 Whitehawk Therapeutics shares in Q2 2026, an estimated $340K.
  • Whitehawk Therapeutics made up 0.81% of Stempoint Capital's portfolio in Q2 2026, its #39 holding.
  • Stempoint Capital first reported a position in Whitehawk Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.